Cyclacel Pharmaceuticals (CYCC) Upgraded to Buy by ValuEngine

ValuEngine upgraded shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) from a hold rating to a buy rating in a report published on Thursday morning.

Other analysts also recently issued research reports about the company. Roth Capital set a $8.00 price target on Cyclacel Pharmaceuticals and gave the company a buy rating in a research note on Thursday, October 4th. LADENBURG THALM/SH SH assumed coverage on Cyclacel Pharmaceuticals in a report on Friday, September 7th. They issued a buy rating and a $6.25 price objective for the company. HC Wainwright set a $7.00 price objective on Cyclacel Pharmaceuticals and gave the company a buy rating in a report on Friday, August 10th. Finally, Zacks Investment Research raised Cyclacel Pharmaceuticals from a sell rating to a hold rating in a report on Monday, October 8th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Cyclacel Pharmaceuticals presently has an average rating of Buy and an average price target of $5.75.

Cyclacel Pharmaceuticals stock traded down $0.04 during trading hours on Thursday, hitting $1.30. 10,944 shares of the stock traded hands, compared to its average volume of 123,175. Cyclacel Pharmaceuticals has a 1 year low of $1.14 and a 1 year high of $2.25.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.04). On average, research analysts forecast that Cyclacel Pharmaceuticals will post -0.59 earnings per share for the current year.

An institutional investor recently raised its position in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC grew its stake in Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 513.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 91,400 shares of the biotechnology company’s stock after buying an additional 76,500 shares during the quarter. Renaissance Technologies LLC owned 0.76% of Cyclacel Pharmaceuticals worth $130,000 as of its most recent SEC filing. Institutional investors and hedge funds own 5.61% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Further Reading: Terms to Better Understand Call Options

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply